Breaking Finance News

Northland Capital reiterated ValiRx PLC (LON:VAL) to Corporate in a report released today.

Just yesterday ValiRx PLC (LON:VAL) traded 6.90% higher at 7.25GBX. ValiRx PLC’s 50-day moving average is 7.60GBX and its 200-day moving average is 8.56GBX. The last closing price is down -9.46% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 956,999 shares of VAL traded hands, down from an average trading volume of 1,429,050

Northland Capital has reiterated ValiRx PLC (LON:VAL) to Corporate in a report released on 10/13/2016.

Recent Performance Chart

ValiRx PLC (LON:VAL)

ValiRx PLC has 52 week low of 5.75GBX and a one year high of 28.01GBX and has a total market value of 0 GBX.

A total of 1 analyst has released a research note on ValiRx PLC. zero analysts rating the company a strong buy, zero brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of 1.05GBX.

Brief Synopsis About ValiRx PLC (LON:VAL)

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *